Maze Therapeutics, Inc. (MAZE)
(Real Time Quote from BATS)
$13.99 USD
-0.91 (-6.11%)
Updated Aug 4, 2025 11:10 AM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MAZE 13.99 -0.91(-6.11%)
Will MAZE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MAZE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for MAZE
12 Health Care Stocks Moving In Monday's After-Market Session
This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Maze Therapeutics (MAZE) Receives Buy Rating from HC Wainwright & Co. | MAZE Stock News
Maze Therapeutics (MAZE) Receives Positive Rating and Outlook | MAZE Stock News
Maze Therapeutics initiated with bullish view at H.C. Wainwright, here's why